Komori
CanBas (4575) · InitiativeRestated

Drug Discovery Research Using AI (Artificial Intelligence)

First written in FY2025. 3 of 7 entries say "Restated". Latest entry: FY2026.

7entries
2years
4from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2025 – 2026-05-14Advanced2026-05-14 – 2026-08-122025: 120252026: 62026
Same theme, other companies
Advancing Drug Discovery Research through AI and InformaticsA theme 13 companies write about · 0 as a headwind · 17 as a tailwind

2 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「The Company is conducting exploratory research and preparing for development to expand its pipeline for the creation and development of new drug candidates, including the immune switch activators CBT005 and CBP-A08, IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Culture, and drug discovery research using AI (artificial intelligence).」

    The Company continues exploratory research and development preparations for new candidate compounds, including AI-based drug-discovery research.
  2. FY2026-H1RestatedAnnual report

    「The Company is conducting exploratory research and preparing for development to expand its pipeline for the creation and development of new drug candidates, including the immune switch activators CBT005 and CBP-A08, IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Culture, and drug discovery research using AI (artificial intelligence).」

    The Company continues exploratory research and development preparations for new candidate compounds, including AI-based drug-discovery research.
  3. FY2025First statedAnnual report

    「In addition to advancing the development of these 2 drug candidates, the Company is conducting exploratory research and preparing for development to expand its pipeline for the creation and development of new drug candidates, including the immune switch activators CBT005 and CBP-A08, which were created based on new insights obtained during this development, IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Culture, and drug discovery research using AI (artificial intelligence).」

    As part of exploratory research and development preparation aimed at expanding its subsequent pipeline, the Company has explicitly identified drug discovery research using AI (artificial intelligence) for the first time.
Moved together

"Efficacy and safety risks in future clinical trials of CBP501" moved the same way as this thread, in the same document, in 2 of its 7 moves.

222★123
  1. ★This thread
  2. 1Efficacy and safety risks in future clinical trials of CBP5012×
  3. 2Next-Generation CBP Project Based on New Findings from CBP5012×
  4. 3R&D operating model combining a small-team structure with outsourcing2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for CanBas yet. It last moved in the Other Disclosures of 2026-08-31: "Cited as achieved".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Drug Discovery Research Using AI (Artificial Intelligence) | CanBas Co.,Ltd. (4575) | Komori